Oryzon Genomics, S.A. announced that Dr. Saikat (?Sai?) Nandi has been appointed as Global Chief Business Officer (CBO). The appointment strengthens Oryzon's permanent presence in the US as Oryzon builds out strategic partnerships. Dr. Nandi?s extensive scientific, business development and financing background will be key to Oryzon in developing partnerships with pharmaceutical companies, and with strategic and financial investors. He is a 15-year life science industry veteran who has served as an investor, business operator, entrepreneur and researcher. He joins Oryzon from AIG Investments where he was a Portfolio Manager overseeing AIG?s Healthcare and Life Science public and private investments, and was previously a Healthcare Investment Advisor at GC Finance. Between AIG and GCF, Dr. Nandi managed public and private healthcare investments totaling more than $1 billion. Before that, he served as Business Development Consultant at the New York State Center for Biotechnology, overseeing the financing and corporate collaborations for over 20 portfolio companies.